Literature DB >> 16728965

Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil.

J R Haaga1, A Exner, B Fei, A Seftel.   

Abstract

The physiologic variability of blood flow to the prostate has not been studied until this time. We report the vasoactive effects of sildenafil and phenylephrine on blood flow of the normal prostate. Sildenafil increases prostate blood flow by approximately 75% and phenylephrine reduces the flow incrementally. Administration of these drugs with dynamic contrast-enhanced magnetic resonance imaging may improve the diagnosis of cancerous tissue because according to the literature, tumor angiogenic vessels lack the vasoactive physiologic response of the normal tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728965      PMCID: PMC3779690          DOI: 10.1038/sj.ijir.3901486

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  18 in total

1.  Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.

Authors:  A R Padhani; C J Gapinski; D A Macvicar; G J Parker; J Suckling; P B Revell; M O Leach; D P Dearnaley; J E Husband
Journal:  Clin Radiol       Date:  2000-02       Impact factor: 2.350

2.  Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma?

Authors:  R H Oyen
Journal:  Eur Radiol       Date:  2003-05       Impact factor: 5.315

Review 3.  Interventional CT: 30 years' experience.

Authors:  John R Haaga
Journal:  Eur Radiol       Date:  2005-11       Impact factor: 5.315

4.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Authors:  A Eberhard; S Kahlert; V Goede; B Hemmerlein; K H Plate; H G Augustin
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

5.  Effects of sildenafil on human penile blood vessels.

Authors:  P Medina; G Segarra; J M Vila; C Domenech; J B Martínez-León; S Lluch
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

6.  Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model.

Authors:  Chao-Nan Qian; Masayuki Takahashi; Richard J Kahnoski; Bin Tean Teh
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

Review 7.  Priapism.

Authors:  Hossein Sadeghi-Nejad; Vikram Dogra; Allen D Seftel; Mamdouh A Mohamed
Journal:  Radiol Clin North Am       Date:  2004-03       Impact factor: 2.303

8.  Enhancement patterns of prostate cancer in dynamic MRI.

Authors:  Paolo Preziosi; Antonio Orlacchio; Guido Di Giambattista; Paolo Di Renzi; Luigi Bortolotti; Alfredo Fabiano; Enrico Cruciani; Patrizio Pasqualetti
Journal:  Eur Radiol       Date:  2002-11-14       Impact factor: 5.315

9.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells.

Authors:  A Preston; M Frydenberg; J M Haynes
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

10.  Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate.

Authors:  Stefan Uckert; Matthias Oelke; Christian G Stief; K-E Andersson; Udo Jonas; Petter Hedlund
Journal:  Eur Urol       Date:  2006-01-18       Impact factor: 20.096

View more
  2 in total

Review 1.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

2.  Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia.

Authors:  Esref O Guven; Mevlana D Balbay; Kilciler Mete; Ege C Serefoglu
Journal:  Int Urol Nephrol       Date:  2008-07-22       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.